
The Motley Fool: Undervalued and growing
The Fool’s Take Bristol Myers Squibb has been pummeled in 2025, creating a rare buying opportunity for investors willing to look past short-term headwinds. The company recently traded at a low forward-looking price-to-earnings (P/E) ratio of 7 — versus …